

## Index

- Abelson virus, 178
- A cell, 186, 211, 218
  - activation, 204
  - confused, 203
  - second signal, role of, 202
- Adrenalectomy, 152
- Aging, cellular, commitment theory of, 5
- Allodeterminant, 93
- Alloreactivity, 93
- Allosteric transition model, *see* T cell
- ALS, *see* Antilymphocytic serum
- Amino acid sequence of cell-surface protein, 123
- Anaphylaxis in mouse, 255–256
- Anchorage of cell
  - dependence, 6
  - growth
    - anchorage-dependent, 6–9, 69
    - anchorage-independent, 69
    - mutation to, 13–14
  - independence, 6, 13, 14
- Angiogenesis, on the pathway to cancer, 5
- Animal model, immune-deficient, 37
- Anti-I-A-antiserum treatment, 96
- Antibody
  - anti-idiotypic, autologous, suppressive, 228, 232–234
  - anti-Ig, 190, 192
  - associative, 25
  - binding, 49
  - class, 260
  - constant region, 283
  - embryonic, identified, 124
  - growth-inhibiting, titration of, 176
- Antibody (*cont.*)
  - homocytotropic, 265
  - humoral, 34
  - monoclonal, 117–137
    - and tumor antigens, 117–137
  - multispecificity receptor, 193
  - production of, 227
  - in serum after antigenic stimulation, 232
  - specificity, 189
    - analysis, 174
  - symmetry, a novel feature, 186
  - therapy with, 131
  - tumor-specific, 132
- Antigen, 123–126
  - antibody complex, 227
  - binding receptor on T cell, 235
  - binding study, 48
  - carcinoembryonic, 127, 129
  - of carcinoma of colon, 129
  - concentration
    - relationship between class and response, 29
  - density, 35
  - differentiation, 123
  - effector system, 35
  - embryonic, 123
    - expression of, 123
  - fibroblast, 125
  - Forssman, 124
  - helper, specific for, 196–197
  - Ia-like, 143
  - of I region on macrophage, 210, 216
  - K/D, 210, 216
  - of leukemia, 130–131

- Antigen** (*cont.*)  
 of leukocyte, 123  
 Lyt differentiation, 83  
 of melanoma, 123, 128  
 of neuroblastoma, 129  
 oncofetal, 123, 124  
 -presenting cells, 86, 107  
 protein, 123  
 and radiation in rabbit, 247-252  
 receptor  
   density, 35  
   number per cell, 29  
 recognition, 31  
   abnormal, 29-31  
   associative, 23, 28-31, 34-37  
   dissociative, 29-31, 36, 37, 51  
   normal, 29-31  
   restrictive, 34, 36, 37  
   suppression, 51  
 sabotage, 51  
 of sarcoma, 122  
 sensitive cell, 35-36  
   analysis, serological, 118  
   avidity for antigen, 29  
   cooperating system, 24  
   effector, induced, 23  
   glycolipid, 124  
   induction, pathway of, 24  
   killer, 24  
   priming, 24  
   suppressor, 24  
   surface of cell, 122  
   of tumor, 124  
 -specific factor  
   antibody production against, 275-289  
   structure of, 282  
 SSEA-1, 124  
 suppressor, 196-197  
 thymus-independent, 57  
 of tumor, 81-116  
   -associated, 44, 49, 50, 127-131  
   immune response to, 81-116  
   monoclonal antibodies to, 117-137  
   in mouse, 122, 123  
   regulation  
     cellular, 81-116  
     genetic, 81-116  
   rejection by strong virus-induced, 38  
   specific, 117, 125, 133  
   transplantation antigen, 90, 118
- Anti-Ig**, 190  
 cross-linking in stimulation by, 192
- Anti-idiotypic**, 228  
 antibody, 232-234
- Antilymphocyte serum**, 190
- Anti-SF immunoadsorbent**  
 effect on the immune response, 278-279
- Ascaris extract**, 257
- Ascites**  
 fluid, 121  
 tumor, 121
- Assay**  
 binding, 120  
 colony-inhibiting, 45-48  
 cytotoxicity, 47-48, 120  
 growth inhibition, 175  
 leukocyte adherence inhibition, 130  
 lymphocyte proliferation, 145  
 migration inhibition, 127  
 protein A, labeled, 120
- Augmentation of response**, 279
- Autoimmunity**, 30, 51, 53
- Autoradiography**, 120
- Azophenylarsonate hapten**, 238
- B cell**, 36, 37, 82, 130-132, 143, 180, 212, 228-239, 256, 262  
 definition of idiotype, 229-233  
   serologic, 230  
 factor, 284  
 idiotype, definition of, 229-233  
   serologic, 230  
 induction, model of, 204  
 lymphoblastoid line, 140  
 lymphoma, 134  
 product, 230  
 radiosensitive, 262  
 and second signal, 195  
   nonspecific activating factors, listed, 198-199  
 stimulated, 190  
 and T-cell interaction, 35, 82-88  
*See also* T cell
- BGG immunization of rabbit**, 252
- Blood cell, human**  
 mononuclear, 262
- B memory cell**, 237-240
- Bordetella pertussis**, 257
- Cancer**  
 autochthonous, development of, 2  
 evasion, 69  
 model for suppression of, 16  
 pathway to, 2-20

- Cancer (*cont.*)  
 pathway to (*cont.*)  
 and angiogenesis, 5–6  
 escape from senescence, 3–5  
 growth and anchorage  
 dependent, 6–9  
 independent, 6–20  
 mutation from dependent to independent, 9–14  
 and metastasis, 5–6  
 and somatic cell evolution, 1–79  
 therapy with human immunoglobulin, 133  
 transformation, 69  
 versus tumor, 14  
 tumorigenicity, 14–18
- Carcinoembryonic antigen, 129
- Carcinoma of colon, antigens, 129
- Cell  
 aging, commitment theory of, 5  
 amino acid sequence of surface protein, 123  
 anchorage, 6–9, 13–14, 69  
 antigens on surface, 122–123  
 sensitive, 26  
 evolution and cancer, 1–79  
 interaction, 35, 82–88  
 line  
 3T3, 11  
 BHK21, 12  
 -mediated immunity (CMI), 81  
 neoplastic, defined, 171  
 saturation density, 149  
 set, immunologic, 227–244  
 somatic, 1–79  
 surface protein, 123  
 transformation, 6
- Central nervous system (CNS), and immune system, 220
- Chromium-release assay, 120
- Chromosome, human, 10
- Clone  
 antibody-producing, 4  
 cytolytic, 142
- CMI, *see* Cell-mediated immunity
- CNS, *see* Central nervous system
- Colon carcinoma, antigens of, 129
- Colony-inhibiting assay, 45–48
- Commitment theory of cellular aging, 5
- Complement and lysis, 34
- Concanavalin A, 140
- Conformational change model, a competing theory, 187–188
- Constant region, *see* Antibody, constant region
- Cooperating activity, 25–26, 28
- Cross-absorption, 49
- Cross-competition, 49
- Cryopreservation, 121
- CTLL, *see* T cell, cytolytic
- Cyclophosphamide, 42
- Cytotoxicity  
 assay, complement-dependent, 128  
 cell-mediated, antibody-dependent, 82  
 lymphocyte-mediated, 127  
 of T<sup>K</sup>, 62–64  
 escape from activity, 62–64
- Deoxyribonucleic acid, *see* DNA
- DNA  
 content, 176  
 melting curve, 215  
 synthesis, 173  
 virus, oncogenic, 157
- DTH, *see* Hypersensitivity, delayed-type
- EB virus, *see* Epstein-Barr virus
- Effector cell, *see* T cell
- Epstein-Barr virus, 140
- Escape from cancer, 65
- Evasion in cancer, 69–71  
 immune mechanisms as a major mechanism, 70
- FACS, *see* Fluorescence-activated cell sorter
- Factors  
 assay methods for, 277  
 messenger molecules, soluble, 275  
 production of antiserum to, 277  
 production methods for, 277  
 structure, model of, 282–285
- α-Fetoprotein, 124
- Fibroblast, 11  
 antigens of, 125  
 human, 4  
 of prostate, 47  
 transformed, 18, 19
- Fibrosarcoma, 89
- Fluorescence-activated cell sorter analysis, 159, 160, 166
- Friend leukemia virus  
 erythroleukemia cells transformed by, 140  
 -induced disease, 88
- Gene product V<sub>H</sub>, 227–244
- Genome, viral, 11

- Glucocorticoid hormone, 152  
 Glycolipid, 123  
 Glycoprotein, 228  
 Gross virus-induced disease, 88  
 Growth model in cancer, 7, 9
- H-2, 213  
   antigen, 208  
   cell surface, structure of, 89  
   restriction, 185-226  
     concept, 192  
     model, 31  
   and network theory, 185-226  
   phenomenon, 214
- Hapten, 87  
 Helper factor, antiserum against, 281  
 Hemolysin titer in mouse, preimmunized  
   after whole-body radiation, 258
- HF, *see* Helper factor  
 Histamine release, 194  
 Homocytotropic antibody, 265  
 HOPC-8, *see* Myeloma protein  
 Hormone, glucocorticoid, 152
- Hybridoma, 118-121  
   antibodies, 120-122  
     production, 121  
   antigen, human myeloma, 128  
   culture medium, 121  
   difficulty in selecting a specific, 132  
   mass culture, 121  
   surface antigens identified by  
     characterization, 121-123  
     purification, 121-123  
   technique revolutionizing tumor serology,  
     118, 128, 130, 131
- Hypersensitivity, delayed-type, 86  
 Hypochromicity, 215
- Ia antigen, 283  
   Ia-like antigen, 143
- Idiotype, 228-238  
   anti-idiotypic antibody, expression of, 233  
     cross-reactive, 229, 231  
   on B cell, 229-233  
   expression, 229, 231, 233  
   gene location for, 230  
   and linkage, 229-233  
   network model for, 233  
   protection, specific, 236  
   on T cell, 229-233  
   secretion suppressed by, 235, 238  
   for V region, 186
- IgE system, 193  
 Immune cell, assay for, 83  
 Immune response  
   mechanism, 70  
   radiation-induced augmentation of, 245-  
     274  
   to tumor antigen, 81-116  
   and tumor escape mechanism, 65
- Immune surveillance, 37  
 Immune system, 21, 71, 220, 228  
   and the central nervous system, similar-  
     ities, 220
- Immunity  
   and invading virus, 81  
   regulation, 235  
   to transplanted tissue, 81  
   and tumor, 49
- Immunodiffusion, 121  
 Immunoendocrinology, 154  
 Immunofluorescence of membrane, 49, 128  
 Immunogenic tumor cells, 254-255  
 Immunoglobulin for human cancer therapy,  
   133; *see also* IgE system
- Immunoprecipitation for the screening of  
   hydromas, 120
- Immunoselection, 40  
 Immunosuppression, 152
- Induction, 22  
   of antigen-sensitive cells, 27  
   of effector end cells, 27  
   of memory cells, 27  
   of response, hierarchical relationships, 26
- Interaction, cellular, 82-88
- Interferon, 146  
 Interleukin, 2, 139  
 Interspecies hybrids (human-mouse), 9-12,  
   15
- Irradiation, *see* Radiation
- K/D antigen, 210  
 Killer cell, 24  
   and cancer, 66  
   mechanism, 36
- Kirsten sarcoma virus, 124
- Lectin, 145, 153; *see also* Concanavalin A
- Leukemia, 130-131  
   in AKR mouse, 169  
   cells, 145  
     surface antigen, 118  
   murine leukemia virus (MuLV), 123  
   of thymic origin, 169

- Leukemogenesis**, 88  
   receptor-mediated model of, 173  
   virus-induced  
     hypothesis, 158  
     produced by antigenic stimulation of transformed cell, 158
- Leukocyte**  
   adherence inhibition assay, 130  
   migration inhibition assay, 128
- Lymphoid cell**  
   in idiotype-suppressed animal, 237  
   receptors, cross-linked, 185  
   stimulation, 188–194  
     and cross-linking of receptor, 188–194  
     transformed, 19
- Lymphokine research**, future of, 154
- Lymphoma**, 90–91  
   and B cell, human, 130, 134  
   cells, 157–184  
   growth-inhibition assay, 175  
   radiation-induced, thymic, 166  
     and murine leukemia virus infected, 167  
   and T cell, 134  
   of thymus in AKR mouse, 162
- Lymphomagenesis**, 157
- Lymphopoietic disease**, 152
- Linkage**, between idiotype expression and heavy chain allotype locus, 229
- Lipopolysaccharide**, 189
- Liver**, fetal, 42
- Lysis by complement**, 34
- Lysozyme**, 45
- Lyt differentiation antigen**, 83
- Macrophage**, 10, 65, 82  
   factor, 275  
   -lymphocyte interaction, 86
- Major histocompatibility complex (MHC)**, 86, 194, 208, 276  
   allogeneic, 208, 210, 211  
   anti-allo-, 216  
   antigens of, 210–212, 216  
   anti-self, 216
- Malignancy**, *see* Cancer
- Mammal**, immunity in, 81
- Mammary tumor virus (MTV)**, 89
- Mast-cell activation**, 194  
   and receptor cross-linking, 194
- Mastocytoma**, 89
- Maxwell's equation**, 207
- MCA**, *see* Methylcholanthrene
- Melanoma**, human, 122  
   antigens, 127–129  
   serological study of, 127
- Membrane immunofluorescence**, indirect, 128
- Metastasis on the pathway to cancer**, 5–6
- Methylcholanthrene (MCA)**, 41, 46, 83, 125  
   and tumor, 83
- MHC**, *see* Major histocompatibility complex
- Micrococcus lysodeikticus***, 233
- Microcytotoxicity technique**, 130
- Millipore filtration**, 40
- Mineral oil**, 121
- Minor histocompatibility antigen**, 212
- Mitogen**  
   factor, 151  
   model, 187, 189  
   receptor, 187  
   second competing theory, 189
- Mixed lymphocyte culture (MLC)**, 140, 143
- MLC**, *see* Mixed lymphocyte culture
- Moloney virus**, 52  
   lymphoma due to, 51
- MOPC-315 protein**, 236
- Mouse**  
   AKR strain  
     and retrovirus, 18, 78, 163, 172  
     thymic leukemia in, 169  
     thymic lymphoma in, 162  
     thymocyte, 171  
   anaphylaxis, 255–256  
   assay, 40  
   athymic, potential of, 43  
   CFW strain  
     anaphylaxis in, 255–256  
   immune blank model, 41  
   nude, 40, 42  
   restored, 42  
   spleen, 148  
   thymectomized, 42
- Multispecificity concept**, 210  
   single V region, 219
- MuLV**, *see* Murine leukemia virus
- Murine leukemia virus (MuLV)**, 123, 126, 157–184, 250–261
- Mutant**, anchorage-independent, temperature-sensitive, 12
- Mutation**  
   from anchorage dependent to independent, 6–9  
   rate-determining, 1

- Mutation (cont.)**  
 single dominant, 14  
 somatic, 188
- Myeloma, 63**  
 cell function, suppressed, 100-103  
 HOPC-8, 230  
 protein, 230  
 and spleen cell hybrid, 119
- Natural killer (NK) system, 66-70**  
 activity, 67, 68, 70  
 cells, 67-68  
 lysis, 67-68
- Neoplastic cell, defined, 171**
- Network, plus-minus, theory, 185-226**  
 alternative concept, 210-218  
 boundary condition concept, 217  
 cross-linking postulates, 219  
 and H<sub>2</sub> restriction, 185-226  
 Jerne's basic features reviewed, 185  
 plus-minus symmetry, 185-186  
 symmetry in interaction between idiotype  
 and anti-idiotype, 219  
 T cell secretes antigen-specific factor, 219
- Neuroblastoma antigen, 129-130**
- NK, see Natural Killer system**
- Nonself-self discrimination (autoimmunity), 22**
- Paralysis, 21, 22, 28, 54**  
 negative unresponsiveness, 21
- Paratope, 186**
- Peptide mapping, 123**
- Phytohemagglutinin (PHA), 140**
- Phosphorylcholine (PC), 230**  
 binding HOPC-8 myeloma protein, 230
- Plasmacytoma, 63, 89**
- Polyethylene glycol as fusing agent, 119**
- Polyoma, 41**  
 system, 38
- Prehn assay, 45-47**
- Preleukemic cell, 169**
- Priming of antigen-sensitive cell, 27**
- Pristane, 121**
- Probit analysis, 146**
- Rabbit**  
 BGG immunization, 252  
 radiation, 247-252  
 and antigens, 247-252  
 SRBC immunization, 247-261
- Radiation**  
 augmentation of immune response, 245-274  
 and immunosuppression, 245  
 of man, 261-264  
 of mouse, 252-257  
 of rabbit, 247-252  
 of rat, 257  
 of thymus cells, 256, 259
- Radiosensitivity, defined, 267**
- Rat, 259**  
 radiation, whole body, 257  
 spleen, 148
- Receptor, cross-linking, 188-194**  
 and lymphoid cell stimulation, 188-194  
 and mast cell activation, 194
- Recognition**  
 associative of antigen, 34  
 restrictive, 34  
 and antigen-sensitive cell, 34  
 sabotage, 51  
 theory, 33-34  
 associative, 21, 33  
 restrictive, 21, 33
- Repressor, 10**
- Response and antigens, 23, 25, 27, 29**
- Restriction of antigen recognition, 31-33**
- Retrovirus, 157**  
 in AKR mouse strain, 163, 172, 178  
 binding specificity, listed, 165  
 binding to T-lymphoma cells and subsequent infection, 164  
 SL, 170, 172  
 surface of cell, 159
- Reverse transcriptase, 168**
- Rous sarcoma virus (RSV), 89**
- RSV, see Rous sarcoma virus**
- Sabotage, 51-54**  
 by abnormal induction, 53  
 by deregulation of autoimmunity, 53-54  
 as an escape mechanism, 56-62  
 with neutrality, 57  
 by sneaking through, 54-56
- Salmonella minnesota, 125**  
 glycolipid coated on, 125
- Sarcoma, 91**  
 in mouse, 122  
 chemically induced, 125  
 ultraviolet light-induced, 103  
 and viruses, 157

- Self
  - altered, receptor models, 209
  - nonself discrimination (autoimmunity), 22
- Senescence assay, 4
- Separate-site binding, 213
- SF, *see* Suppressor factor
- Shape space, 211
- Signal, 2, 30, 51
- Simian virus 40, *see* SV40
- Skin graft, 254
- SL virus, 170
- Spleen cell, 263–264, 268–269
  - APC function, 107
  - and myeloma cell hybrid, 119
- Splenocyte, *see* Spleen cell
- SRBC immunization
  - of mouse, 252–255
  - of rabbit, 247–250
  - of spleen cell, 268–270
- Stable-state model
  - anti-immune, 201
  - immune, 201
  - suppressed, 201
  - virgin-state, 201
- Staphylococcus aureus*, 122
  - protein A, 284
- Streptococcal-A carbohydrate, 239
- Suppression, 21, 27, 28, 54–57
  - as escape mechanism, 56
  - induction, 61
    - dissociative (abnormal), 30
  - with neutrality, 57
  - origin, 61
  - role in autochthonous tumor, 60
  - specificity, 61
  - unresponsiveness, positive, 21
- Suppressor cell, 24, 98, 101, 102
  - B cell, 102
  - circuits, 99–100
  - macrophage, 102
  - T cell, 98–110
- Suppressor factor (SF), 276
  - mouse antiserum to, 280–281
  - rabbit antiserum to, 278–280
- Surface determinant
  - density, 35
  - and target cell, killing of, 35
- Surveillance
  - defective, 3
  - extracellular, 3
- Surveillance (*cont.*)
  - immune, 3
  - intracellular, 3
  - nonimmune, 3, 66
- SV40, 64, 83
  - transformation of human cells by, 10–11
  - tumor induced by, 118
- Syngeneic tumor antigen
  - immune response to, 82
- Target cell, killing of, 35
- T cell, 21, 41, 51, 58, 65, 86, 180, 186, 210, 211, 218, 228–239, 256
  - antigen
    - receptor, 143, 235
    - recognition, 34–37
    - specific, 139
  - assay for, 286
  - B-cell interaction, 35, 84–85, 275
  - connectance as a concept, 207
  - culture method, 145
  - cytolytic, 94, 139–145
  - cytotoxic, continuous cell line, 139–155
  - doughnut model, 211–212
  - effector, 27, 31–34, 82–85, 93–98
  - escape from cytotoxicity, 62–64
  - factor, 195, 216, 217
  - growth factor, 139, 148–153
    - assay for, 145–148
    - immunobiology of, 151–153
    - production, 148–149
    - specificity of absorption, 150
  - helper cell, 36, 37, 109, 205, 206, 236–240
    - factor, 275, 276, 284, 286
  - idiotype definition on, 229–231
  - interaction with B cell, *see* T cell, B-cell interaction
  - irradiated, 262
  - killer, 205
  - lymphoma, 134, 157–184
    - proliferation, 173
    - receptor, 177
      - inhibited, 173
    - retrovirus, 164
  - model, mathematical, 205
  - proliferation, 151, 152
  - radiosensitive, 271
  - receptor, 84, 143, 213, 235, 276
  - and stimulation, 190
  - subpopulation, 82

- T cell (*cont.*)
- suppressor, 56, 84, 85, 98–110, 206, 234–238, 276
  - synergy, 82–84
  - and tumor
    - retardation, 144
    - syngeneic, 98
- Temperature sensitivity, 13
- Teratocarcinoma, embryonic, 69
- F9 cell line, 124
- Thymidine, tritiated, 145
- Thymocyte, 152, 153, 171
- Thymoma, 89
- Thymus gland, 157, 172
- cell and radiation, 256
  - cryptic, 41
  - fossil, 41
  - lymphoma, 162
  - radiation and, 256
  - role of, 153
- T lymphocyte, *see* T cell
- Tolerance, 54
- Transformation, 39
- in cancer, 69–70
  - frequency, 19
  - of lymphoid cell, 19
  - neoplastic, 159
- Transition model, allosteric, 187
- Transplantation
- cells, 118
  - procedure, 4
- Tumor
- and anchorage, 14–18
  - antigen, 45, 81–117, 122, 132, 133
    - antibody, monoclonal, to, 117–137
    - and hybridoma for studying, 119
    - immune response to, 44, 81–116
    - recognition, 90
  - ascites, 128
  - autochthonous, 58–62
  - biopsy, 128
  - versus cancer, 14
  - carcinogen-induced, 44
  - chemically induced, 44
  - cytolysis, 141
  - escape mechanism, 21, 50–66
  - experimental tumors seem immortal, 5
  - and H-2 products, 89–90
  - and host interaction, 22, 44, 57, 81–116
  - and hybridoma, 119, 131; *see also* Tumor, serology
- Tumor (*cont.*)
- immunogenic, 44, 45, 117
  - immunoselected, 58, 165
  - induction by UV light, 62, 103
  - and leukemia, human, 130
  - in mouse, 123
  - polyoma-induced, 89
  - rejection, virus-induced, 38
  - resistance to, virus-induced, 88
  - serology, 131; *see also* Tumor, and hybridoma
  - transformation antigen, 125
  - See also* Cancer
- Tumorigenesis, multistage model for, 2
- Tumorigenicity, 14–18
- assay, 37–39
  - correlation between expression of anchorage-dependent and -independent growth, 14
  - in interspecies hybrids, 15–16
- Ultraviolet radiation, 60
- induced skin tumor, 62
  - induced tumor lysis, 108
- Unresponsiveness, *see* Paralysis
- antigen-specific, 21, 22
- in immune regulation, 22
  - negative, 21
  - type of
    - negative, 21, 22
    - positive, 22
- V gene, 229, 231
- V<sub>H</sub> gene product, 227
- V region, 229, 234, 283
- recognition, 234
- Vesicular stomatitis virus, 168
- Virus
- Abelson, 178
  - Epstein-Barr, 140
  - Friend, 88, 140
  - genome, 11
  - Gross, 88
  - integration, 14
  - Kirsten sarcoma, 124
  - mammary tumor, 89
  - Moloney, 51–52, 168
  - murine leukemia, 123, 126, 157–184, 250–261
  - oncogenic, 6, 88, 157, 159
  - passenger, 50



**Virus (*cont.*)**

- polyoma, 38, 41, 89
- retrovirus, 159, 163–165, 170, 172, 178
- Rous sarcoma, 89
- sarcoma, 157
- SL, 170
- SV40, 10–11, 64, 83, 118
- tumor rejection by, 38
- vesicular stomatitis, 168

- Winn-type experiment, 102
- Whole body radiation by UV, 252
  - in humans, 261–264, 268
- X antigen, 213, 214
- Xenoinmunization, 127, 131
- X rays, 42